An update on Alectinib: a first line treatment for ALK-positive advanced lung cancer-Reference-Cited by-同舟云学术

An update on Alectinib: a first line treatment for ALK-positive advanced lung cancer

Published:2023-06-13 Issue:12 Volume:24 Page:1361-1373
ISSN:1465-6566
Container-title:Expert Opinion on Pharmacotherapy
language:en
Short-container-title:Expert Opinion on Pharmacotherapy

Author:

Zhou Yourong¹,Yin Yiming¹,Xu Jiangxin¹²,Xu Zhifei¹^ORCID,Yang Bo³^ORCID,He Qiaojun¹⁴^ORCID,Luo Peihua¹⁵^ORCID,Yan Hao¹^ORCID,Yang Xiaochun¹^ORCID

Affiliation:

1. College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, China

2. Department of Pharmacy, Hangzhou Red Cross Hospital (Hangzhou Chest Hospital Affiliated to Zhejiang University Medical College), Hangzhou, China

3. Institute of Pharmacology & Toxicology, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, China

4. Innovation Institute for Artificial Intelligence in Medicine, Zhejiang University, Hangzhou, China

5. Department of Pharmacology and Toxicology, Hangzhou Institute of Innovative Medicine, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, China

Funder

National Natural Science Foundation of China

Publisher

Informa UK Limited

Subject

Pharmacology (medical),Pharmacology,General Medicine

Link

https://www.tandfonline.com/doi/pdf/10.1080/14656566.2023.2221786

Reference116 articles.

1. Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC

2. Pembrolizumab plus Chemotherapy in Metastatic Non–Small-Cell Lung Cancer

3. Updated overall survival and final progression-free survival data for patients with treatment-naive advanced ALK-positive non-small-cell lung cancer in the ALEX study

4. The function and therapeutic targeting of anaplastic lymphoma kinase (ALK) in non-small cell lung cancer (NSCLC)

5. Three-Year Follow-Up of an Alectinib Phase I/II Study in ALK-Positive Non–Small-Cell Lung Cancer: AF-001JP